Akero Therapeutics, Inc. Soared

Akero Therapeutics, Inc. (AKRO:NASDAQ) jumped higher at $51.71, representing a gain of 97.5%. On Mon, Jan 27, 2025, AKRO:NASDAQ hit a New 2-Week High of $51.71. The stock got featured on our News Catalysts scanner on Mon, Jan 27, 2025 at 05:30 PM in the 'PUBLIC OFFERING' category. From Mon, Jan 13, 2025, the stock recorded 77.78% Up Days and 40.00% Green Days

About Akero Therapeutics, Inc. (AKRO:NASDAQ)

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical need. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate AKR-001 is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.